Skip to main content
. Author manuscript; available in PMC: 2015 Jun 13.
Published in final edited form as: Mol Imaging Biol. 2008 Jun 10;10(5):271–280. doi: 10.1007/s11307-008-0151-6

Fig. 5.

Fig. 5

The hematological measurements show no significant declines in WBC, ANC, RBC, Hgb, or platelets except in patient 4 where the declines were due to bevacizumab and irinotecan. Haptoglobin levels show no evidence of hemolysis.